4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery.
News & Library
Appointment of Professor Akiko Iwasaki to Scientific Advisory Board. Professor of Molecular, Cellular and Developmental Biology and Immunology at Yale University - Principal investigator at the Howard Hughes Medical Institute. Brings extensive experience in Immunology within the field of infectious diseases, most recently in COVID-19.
4BIO Capital announces its investment in Araris Biotech AG, a company pioneering an antibody-drug conjugate (ADC)-linker technology. Araris announced today that it has received an additional CHF 12.7 million in its seed financing round, bringing the total amount raised to CHF 15.2 million. Dmitry Kuzmin, Managing Partner at 4BIO Capital, will join Araris’ Board.
4BIO Capital announces its investment in SparingVision, a genomic medicine company focused on ocular diseases.
4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board
4BIO Capital appoints Brian P. McVeigh, a seasoned pharma and biotech industry veteran, as Venture Partner to strengthen 4BIO Capital’s US operations. 1 July 2020
4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin. 8 June 2020
4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million 20 May 2020
Redpin Therapeutics secures initial closing of $15.5 million in Series A financing. 4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors. 25 March 2020
Discussion of Covid19 and cyber security. 20 April 2020
Discussion on background, progress, and impact of Covid19. 19 March 2020
Media Coverage of the Ventures II Launch 9 September 2019
4BIO Capital raises $50 million in first close of new advanced therapies fund. 4BIO Ventures II fund solely focused on advanced therapies. 9 September 2019